CAR T-cell therapy (MabVax Therapeutics Holdings/Memorial Sloan Kettering Cancer Center/Juno Therapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameCAR T-cell therapy (MabVax Therapeutics Holdings/Memorial Sloan Kettering Cancer Center/Juno Therapeutics)
Drug Alias Namechimeric antigen receptor expressing T-cells (MabVax Therapeutics Holdings/Memorial Sloan Kettering Cancer Center/Juno Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMabvax Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMabvax Therapeutics Holdings IncMemorial Sloan Kettering Cancer CenterJuno Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A